Let The Numbers Speak: Prescription Drug Provisions In The Inflation Reduction Act
The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse incentives for the biopharma industry.
The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse incentives for the biopharma industry.
What's Your Reaction?
